Clinical Trial Update: Tarceva and Capecitabine for Pancreatic Cancer [Phase 2]

View source ↗

Summary

A completed Phase 2 trial evaluating Tarceva (erlotinib) in combination with Capecitabine for pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Tarceva (erlotinib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Pancreatic Cancer, Neoplasm Metastasis | Phase 2 | Status: COMPLETED